China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

A stand-alone sequencing approach was accurate, cost effective and efficient for analyzing resistant pathogens and ...

Beijing’s action against clothing maker PVH and biotech company Illumina underlines risk created by trade tensions ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

Shares of gene-sequencing leader Illumina have fallen 15% from Friday. Rivals 10X Genomics and Pacific BioSciences of ...

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Market OverviewThe Global Carrier Screening Market is a genetic testing process that determines whether an individual carries ...

The top opportunities in the genomic data analysis and interpretation market segmented by end-user will arise in the pharmaceutical and biotechnology companies segment, which will gain $756.71 million ...

Precision medicine is an innovative approach in healthcare that takes into account individual differences in genes, ...